
Chemotherapy and Emetogenic Potential
See eviQ for international guidelines in prevention of antineoplastic-induced nausea and vomiting.
High (>90% risk)
- Allogeneic SCT ablative conditioning schedules
- Cisplatin
- Carmustine (BCNU) (used in BEAM)
Moderate (30-90% risk)
- Total Body Irradiation (TBI)
- Most RIC conditioning schedules
- Cyclophosphamide IV
- Carboplatin
- Doxorubicin >75 mg/m2
- Cytarabine ≥1000 mg/m2
- Melphalan in high dose ( ≥140 mg/m2)
- Methotrexate ≥250 mg/m2
- Idarubicin
- Ifosfamide
- Daunorubicin
- Etoposide (VP16) IV
- Mitoxantrone
Low (10-30% risk)
- Doxorubicin (liposomal)
- Gemcitabine
- Fludarabine
Minimal (<10%)
- L-asparaginase
- Chlorambucil
- Vincristine
- Vinblastine
- 6-thioguanine (oral)
- Cyclophosphamide (oral)
- Oral melphalan
- Busulphan
- Bleomycin
- Rituximab
- Alemtuzumab
- Bortezomib
Topic Code: 9326